09/27/23 9:09 AMNasdaq : ALLO Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingSpotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune Cells Evaluation of Cloak™ Technology to Engineer AllogeneicRHEA-AIneutral
09/05/23 8:30 AMNasdaq : ALLO Allogene Therapeutics Announces Participation in September Investor ConferenceAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investorRHEA-AIneutral
09/05/23 7:00 AMNasdaq : ALLO Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.Cantor Fitzgerald, L.P., a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D., to its Healthcare and Biotechnology Research platform. Pascal Bandelier, Senior Managing...RHEA-AIpositive
08/14/23 8:30 AMNasdaq : ALLO managementAllogene Therapeutics Appoints Earl Douglas as General CounselAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as GeneralRHEA-AIneutral
08/02/23 4:02 PMNasdaq : ALLO earningsAllogene Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatePresented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International Conference on Malignant Lymphoma (ICML) Lugano ALLO-501/501A Demonstrated Rates of DurableRHEA-AIneutral
07/26/23 8:30 AMNasdaq : ALLO conferencesearningsAllogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, todayRHEA-AIneutral
06/15/23 9:30 AMNasdaq : ALLO clinical trialAllogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) LuganoPresentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose Regimen Results Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete ResponsesRHEA-AIneutral
06/14/23 8:00 AMNasdaq : ALLO Allogene Therapeutics Announces Departure of Chief Financial OfficerAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph.D.,RHEA-AIneutral
06/09/23 6:25 PMNasdaq : ALLO clinical trialAllogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) LuganoLong-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR TRHEA-AIneutral
06/03/23 9:00 AMNasdaq : ALLO clinical trialAllogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual MeetingLong Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen 67% Overall Response Rate (ORR) and 58%RHEA-AIneutral